AU2013239070A1 - Cellular markers for diagnosis of Alzheimer's disease and for Alzheimer's disease progression - Google Patents
Cellular markers for diagnosis of Alzheimer's disease and for Alzheimer's disease progression Download PDFInfo
- Publication number
- AU2013239070A1 AU2013239070A1 AU2013239070A AU2013239070A AU2013239070A1 AU 2013239070 A1 AU2013239070 A1 AU 2013239070A1 AU 2013239070 A AU2013239070 A AU 2013239070A AU 2013239070 A AU2013239070 A AU 2013239070A AU 2013239070 A1 AU2013239070 A1 AU 2013239070A1
- Authority
- AU
- Australia
- Prior art keywords
- lin
- cells
- cd11b
- level
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615465P | 2012-03-26 | 2012-03-26 | |
| US61/615,465 | 2012-03-26 | ||
| PCT/IL2013/050277 WO2013144957A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013239070A1 true AU2013239070A1 (en) | 2014-11-13 |
Family
ID=49258360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013239070A Abandoned AU2013239070A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of Alzheimer's disease and for Alzheimer's disease progression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150057176A1 (https=) |
| EP (1) | EP2831584B1 (https=) |
| JP (1) | JP6276252B2 (https=) |
| KR (1) | KR20140145173A (https=) |
| CN (1) | CN104471394B (https=) |
| AU (1) | AU2013239070A1 (https=) |
| CA (1) | CA2907909A1 (https=) |
| ES (1) | ES2819174T3 (https=) |
| IL (1) | IL234779A (https=) |
| WO (1) | WO2013144957A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6312302B2 (ja) * | 2014-01-06 | 2018-04-18 | 公益財団法人ヒューマンサイエンス振興財団 | 脳梗塞の診断マーカー |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP6499342B2 (ja) * | 2018-03-19 | 2019-04-10 | 隆樹 日和佐 | 脳梗塞の診断マーカー |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| US20220170908A1 (en) * | 2019-03-26 | 2022-06-02 | Anton Wyss-Coray | Compositions and methods for characterizing and treating alzheimers disease |
| CN111727260A (zh) * | 2019-10-15 | 2020-09-29 | 湖南乾康科技有限公司 | 中间型单核细胞在制备诊断和预测ad药物中的应用 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN112562867A (zh) * | 2021-02-22 | 2021-03-26 | 天津迈德新医药科技有限公司 | 一种预测极早期hiv感染风险的装置、存储介质和电子装置 |
| KR20240042044A (ko) | 2021-08-09 | 2024-04-01 | 뉴로퀘스트 엘티디 | 전임상 알츠하이머병을 검출하기 위한 조성물, 키트 및 방법 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| KR102745500B1 (ko) * | 2022-09-02 | 2024-12-23 | 한양대학교 에리카산학협력단 | 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법 |
| CN116270741B (zh) * | 2023-02-28 | 2025-10-24 | 东莞市东南部中心医院 | 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用 |
| CN117122612B (zh) * | 2023-07-07 | 2024-08-27 | 河络新图生物科技(上海)有限公司 | 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1248643E (pt) * | 2000-01-20 | 2005-10-31 | Yeda Res & Dev | Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora |
| US20020137108A1 (en) * | 2000-11-08 | 2002-09-26 | Michael Mullan | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease |
| IL160105A0 (en) * | 2001-12-06 | 2004-06-20 | Yeda Res & Dev | Vaccine for treatment of motor neurone diseases |
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| CN102186504B (zh) * | 2008-09-18 | 2018-04-06 | 西塞医疗中心 | 用于检测阿尔兹海默病的光学方法 |
| US20130230499A1 (en) * | 2010-03-10 | 2013-09-05 | Michal Eisenbach-Schwartz | Cellular blood markers for early diagnosis of als and for als progression |
-
2013
- 2013-03-21 WO PCT/IL2013/050277 patent/WO2013144957A1/en not_active Ceased
- 2013-03-21 CA CA2907909A patent/CA2907909A1/en not_active Abandoned
- 2013-03-21 ES ES13767635T patent/ES2819174T3/es active Active
- 2013-03-21 US US14/388,369 patent/US20150057176A1/en not_active Abandoned
- 2013-03-21 JP JP2015502555A patent/JP6276252B2/ja active Active
- 2013-03-21 EP EP13767635.9A patent/EP2831584B1/en active Active
- 2013-03-21 AU AU2013239070A patent/AU2013239070A1/en not_active Abandoned
- 2013-03-21 KR KR1020147029916A patent/KR20140145173A/ko not_active Withdrawn
- 2013-03-21 CN CN201380027520.5A patent/CN104471394B/zh active Active
-
2014
- 2014-09-22 IL IL234779A patent/IL234779A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20150057176A1 (en) | 2015-02-26 |
| ES2819174T3 (es) | 2021-04-15 |
| EP2831584B1 (en) | 2020-06-17 |
| EP2831584A1 (en) | 2015-02-04 |
| CA2907909A1 (en) | 2013-10-03 |
| JP2015511721A (ja) | 2015-04-20 |
| JP6276252B2 (ja) | 2018-02-07 |
| IL234779A (en) | 2017-12-31 |
| WO2013144957A1 (en) | 2013-10-03 |
| CN104471394A (zh) | 2015-03-25 |
| KR20140145173A (ko) | 2014-12-22 |
| CN104471394B (zh) | 2017-04-05 |
| EP2831584A4 (en) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2831584B1 (en) | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression | |
| Larbi et al. | Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease | |
| Milo et al. | Revised diagnostic criteria of multiple sclerosis | |
| Richartz et al. | Decline of immune responsiveness: a pathogenetic factor in Alzheimer’s disease? | |
| Xu et al. | High prevalence of mild cognitive impairment in the elderly: a community-based study in four cities of the Hebei Province, China | |
| Hatemi et al. | One year in review 2017: Behçet’s syndrome | |
| US20150209404A1 (en) | Cellular blood markers for early diagnosis of als and for als progression | |
| Chen et al. | Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood | |
| Martins et al. | Disease-specific expression of the serotonin-receptor 5-HT2C in natural killer cells in Alzheimer's dementia | |
| Wu et al. | A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's disease | |
| EP3467497A1 (en) | Method for analyzing expression of smn protein nuclear body | |
| Roda et al. | Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage | |
| Green et al. | Blood biomarkers discriminate cerebral amyloid status and cognitive diagnosis when collected with ACD-A anticoagulant | |
| Frisullo et al. | The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis | |
| EP3128327B1 (en) | Method for detecting smn protein expression | |
| CA2941460C (en) | Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing parkinson's disease | |
| Fischer et al. | VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly | |
| Ma et al. | Terminally differentiated cytotoxic CD4+ T cells were clonally expanded in the brain lesion of radiation‐induced brain injury | |
| Bădulescu et al. | Immune thrombocytopenic purpura: Correlations between thrombocytopenia severity and its clinical symptoms | |
| JP4455753B2 (ja) | 精神分裂病の皮膚テスト | |
| Jiao et al. | Confocal Corneal Microscopy in the Evaluation of Immune-related Motor Neuron Disease Syndrome | |
| Traboulsee et al. | Epidemiology & Registry | |
| Yu et al. | Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study | |
| Richartz-Salzburger et al. | Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer’s Disease? | |
| Pender et al. | Correlation of Blood T Cell and Antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |